Literature DB >> 8396590

Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations.

K Y Green1, J F Lew, X Jiang, A Z Kapikian, M K Estes.   

Abstract

Since the discovery of the Norwalk virus (NV) by immune electron microscopy (IEM) in 1972, serologic studies with this virus have relied on particle-positive fecal material from infected volunteers as the source of antigen because it has not been possible to propagate this virus in cell culture. However, the recent cloning of the NV (strain 8FIIa) genome and expression of the capsid protein in a baculovirus system to form "virus-like particles" has provided a consistent source of antigen (designated rNV). The purpose of the present study was to compare the antigenicities of these rNV particles with those of native NV antigen derived from human fecal material by using well-characterized sera obtained from earlier studies. In IEM studies, the rNV antigen reacted with NV-specific antibodies in a manner similar to that observed previously when particle-positive fecal material was used as antigen. In addition, a direct enzyme-linked immunosorbent assay, in which the rNV antigen was used as antigen, proved efficient and specific for the detection of serologic responses to NV compared with the previously established techniques of IEM and blocking antibody immunoassays in which particle-positive fecal material was used as the antigen. The availability of an unlimited source of antigen will enable serologic studies that will greatly increase our understanding of the epidemiology of NV and its role in human enteric illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396590      PMCID: PMC265719          DOI: 10.1128/jcm.31.8.2185-2191.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Prevalence of antibody to the Norwalk agent by a newly developed immune adherence hemagglutination assay.

Authors:  A Z Kapikian; H B Greenberg; W L Cline; A R Kalica; R G Wyatt; H D James; N L Lloyd; R M Chanock; R W Ryder; H W Kim
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

2.  Viral agents associated with acute gastroenteritis in humans.

Authors:  R G Wyatt; A Z Zapikian
Journal:  Am J Clin Nutr       Date:  1977-11       Impact factor: 7.045

3.  Solid-phase microtiter radioimmunoassay for detection of the Norwalk strain of acute nonbacterial, epidemic gastroenteritis virus and its antibodies.

Authors:  H B Greenberg; R G Wyatt; J Valdesuso; A R Kalica; W T London; R M Chanock; A Z Kapikian
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

4.  Diarrhea due to Norwalk virus in families.

Authors:  L K Pickering; H L DuPont; N R Blacklow; G Cukor
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

5.  Norwalk virus genome cloning and characterization.

Authors:  J N Xi; D Y Graham; K N Wang; M K Estes
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

6.  Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults.

Authors:  P C Johnson; J J Mathewson; H L DuPont; H B Greenberg
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

7.  Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity.

Authors:  T Vesikari; T Varis; K Green; J Flores; A Z Kapikian
Journal:  Vaccine       Date:  1991-05       Impact factor: 3.641

8.  Immunoglobulin M responses to the Norwalk virus of gastroenteritis.

Authors:  G Cukor; N A Nowak; N R Blacklow
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

9.  Clinical immunity in acute gastroenteritis caused by Norwalk agent.

Authors:  T A Parrino; D S Schreiber; J S Trier; A Z Kapikian; N R Blacklow
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

10.  Detection of Norwalk virus antibodies and antigen with a biotin-avidin immunoassay.

Authors:  G W Gary; J E Kaplan; S E Stine; L J Anderson
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

View more
  88 in total

1.  Capsid protein diversity among Norwalk-like viruses.

Authors:  J Green; J Vinje; C I Gallimore; M Koopmans; A Hale; D W Brown; J C Clegg; J Chamberlain
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

2.  Molecular cloning, expression, and antigenicity of Seto virus belonging to genogroup I Norwalk-like viruses.

Authors:  S Kobayashi; K Sakae; Y Suzuki; K Shinozaki; M Okada; H Ishiko; K Kamata; K Suzuki; K Natori; T Miyamura; N Takeda
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

3.  Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

Authors:  Anne M Hutson; Robert L Atmar; Donald M Marcus; Mary K Estes
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Interaction of recombinant norwalk virus particles with the 105-kilodalton cellular binding protein, a candidate receptor molecule for virus attachment.

Authors:  M Tamura; K Natori; M Kobayashi; T Miyamura; N Takeda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane.

Authors:  Masaru Tamura; Katsuro Natori; Masahiko Kobayashi; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.

Authors:  Gabriel I Parra; Eugenio J Abente; Carlos Sandoval-Jaime; Stanislav V Sosnovtsev; Karin Bok; Kim Y Green
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

7.  Virological, serological, and clinical features of an outbreak of acute gastroenteritis due to recombinant genogroup II norovirus in an infant home.

Authors:  Takeshi Tsugawa; Kazuko Numata-Kinoshita; Shinjiro Honma; Shuji Nakata; Masatoshi Tatsumi; Yoshiyuki Sakai; Katsuro Natori; Naokazu Takeda; Shinichi Kobayashi; Hiroyuki Tsutsumi
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

8.  Molecular epidemiology of norovirus strains circulating in Ireland from 2003 to 2004.

Authors:  A Waters; S Coughlan; L Dunford; W W Hall
Journal:  Epidemiol Infect       Date:  2006-03-29       Impact factor: 2.451

9.  Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope.

Authors:  Tomoyuki Shiota; Michio Okame; Sayaka Takanashi; Pattara Khamrin; Makiko Takagi; Kenji Satou; Yuichi Masuoka; Fumihiro Yagyu; Yuko Shimizu; Hideki Kohno; Masashi Mizuguchi; Shoko Okitsu; Hiroshi Ushijima
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.